Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Issued
Ratios

Sangamo Therapeutics (SGMO) Other Gross PP&E Adjustments (2016 - 2025)

Sangamo Therapeutics has reported Other Gross PP&E Adjustments over the past 15 years, most recently at $45.9 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $45.9 million for Q4 2025, up 24.5% from a year ago — trailing twelve months through Dec 2025 was $45.9 million (up 24.5% YoY), and the annual figure for FY2025 was $45.9 million, up 24.5%.
  • Other Gross PP&E Adjustments for Q4 2025 was $45.9 million at Sangamo Therapeutics, up from -$14.4 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for SGMO hit a ceiling of $45.9 million in Q4 2023 and a floor of -$70.9 million in Q1 2022.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$19.8 million (2024), compared with a mean of -$24.0 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: soared 1013.48% in 2022 and later decreased 19.82% in 2024.
  • Sangamo Therapeutics' Other Gross PP&E Adjustments stood at -$3.3 million in 2021, then soared by 1013.48% to $30.4 million in 2022, then surged by 51.32% to $45.9 million in 2023, then decreased by 19.82% to $36.8 million in 2024, then grew by 24.5% to $45.9 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $45.9 million (Q4 2025), -$14.4 million (Q3 2025), and -$15.1 million (Q2 2025) per Business Quant data.